Could the Hurricane Energy share price be the bargain of the year?

G A Chester weighs up the potential of exciting oil stock Hurricane Energy plc (LON:HUR) and a pharma firm aiming to rise like a phoenix.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There’s no shortage of loss-making-but-high-potential companies on the stock market. Oil explorers and developers and pharmaceuticals and medical technology firms offer the prospect of particularly big gains for investors who identify the right company at the right price.

Of course, this is easier said than done. For every millionaire-maker there are dozens of duds. Today, I’m weighing up the potential of oil stock Hurricane Energy (LSE: HUR) and pharma player Circassia (LSE: CIR), which released its annual results today.

Collapse

Heavily backed by cornerstone investors Neil Woodford and his protégé at former employer Invesco, Circassia pursued the development of a whole platform of allergy treatments that were said to build immunity quicker than existing remedies and without the risk of anaphylactic shocks. When its lead cat allergy failed a Phase III study, the entire programme collapsed.

At the height of investor confidence, Circassia was a member of the FTSE 250 index, with a share price of 350p and market capitalisation of over £1bn. Today, it’s on the AIM market, its share price is 31.5p (down a little on the back of its results) and its market cap is £118m. Its accounts show an accumulated loss of over half-a-billion quid.

However, it now has a small portfolio of revenue-generating products, including via a commercial collaboration with AstraZeneca, which has also become a 19% shareholder in Circassia. Could the stock be set to rise like a phoenix?

Recovery?

Just over a year ago, I wrote that I wouldn’t touch Circassia with a bargepole, noting also a 5.42% short position in the stock held by hedge fund Mangrove.

Today’s results showed a £37.2m operating loss on revenue of £48.3m. There are signs of promising revenue growth, and with the share price much lower than a year ago, the valuation picture has improved.

However, continued losses are forecast into next decade and Mangrove has maintained its chunky short position. I’m not convinced the risk/reward proposition with Circassia is compelling, and so continue to see it as a stock to avoid at this stage.

Share price to double?

By contrast, when I last wrote about Hurricane Energy (November 2017), I felt its progress to date, potential to become a major player in the West of Shetland region, and share price of 26.75p (market cap £524m) represented an attractive risk/reward proposition. The shares are currently trading at around 47p (market cap £921m), but I continue to see a compelling investment opportunity.

The company is on track to deliver first oil from its 100%-owned Lancaster discovery before the end of June. Planned initial production is 17,000 barrels a day, and management expects to generate over $200m in operating cash flow on a full-year run-rate basis at a $60 a barrel Brent oil price.

Meanwhile, a 50% farm-in to its Warwick and Lincoln fields by Spirit Energy, providing up to $387m, has enabled an acceleration of activity, including the drilling of three wells this year, one of which was spudded last month.

If we see the company successfully executing on this year’s work programme, I think the share price could easily double from its current level. And with total 2P reserves and 2C contingent resources across the asset base standing at 2.3bn barrels net to Hurricane, there’s potential for the value of the company to continue increasing as time goes on.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

Why aren’t people buying Greggs shares by the bucketload?

Greggs' shares remain in the doldrums. But should Foolish investors consider pouncing while others won't? Paul Summers takes a fresh…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

£10,000 invested in easyJet shares 2 days ago is now worth…

easyJet shares just experienced a sharp move higher. So anyone who invested in the budget airline operator two days ago…

Read more »

Wall Street sign in New York City
Investing Articles

I’m getting ready for a dramatic stock market crash

Our writer sees plenty of reasons that could mean a lot of stock market volatility is on the way. But…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£5,000 invested in BP shares 2 days ago is now worth…

BP shares were in a very strong upward trend. However, in the last few days they have pulled back amid…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 top FTSE 250 investment trusts to consider in April

The FTSE 250 is brimming with high-quality investment trusts. Our writer highlights two very different options, including a mid-cap newcomer.

Read more »

Edinburgh Cityscape with fireworks over The Castle and Balmoral Clock Tower
Investing Articles

After making a fortune on Tesla, this FTSE 250 trust has piled into a little-known S&P 500 stock

Baillie Gifford made huge profits from S&P 500 growth stocks like Nvidia. Lately, it's been snapping up a lesser-known tech…

Read more »

ISA coins
Investing Articles

How much do you need in a Stocks and Shares ISA to target a £1,200 a year passive income?

A FTSE 100 index fund comes with a 3% dividend yield. But can income investors find better opportunities for their…

Read more »

piggy bank, searching with binoculars
Value Shares

What’s going on with the Greggs share price now?

Dr James Fox takes a look at the Greggs share price which has suffered more than most over the past…

Read more »